The Impact of a Weight Reduction Intervention on Clinical Outcomes in Patients With Obesity and COPD

NCT ID: NCT07159594

Last Updated: 2025-09-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-01

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obesity and COPD are increasingly common and often coexist, worsening health outcomes such as reduced lung function, exercise capacity, and increased systemic inflammation. While COPD was historically associated with underweight, obesity is now more prevalent among these patients and poses new challenges. Despite some evidence that weight loss may improve lung function, comprehensive interventions have not been fully studied.

The TRIO-COPD study aims to evaluate a 20-week program combining energy restriction, adequate protein intake, and structured exercise in COPD patients with obesity. The study will assess:

Primary outcome:

-Exercise capacity (6-minute walking test).

Secondary outcomes:

-Lung function (spirometry and lung volumes), -symptoms ( assessed via questionnaires), body composition (fat mass, fat-free mass, waist circumference), and inflammatory markers (e.g., IL-6, CRP, CC16).

A subgroup will also undergo sputum analysis.

The study addresses a critical gap, aiming to determine whether structured weight reduction can improve COPD symptoms, reduce inflammation, and limit muscle loss-advancing understanding of obesity's impact on COPD and providing evidence for potential treatment guidelines.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Obesity &Amp; Overweight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Intervention with delayed intervention in the control arm
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Investigator not taking part of the intervention will provide randomisation to start with diet or control

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Energy restriction

One arm will start as control group

Group Type OTHER

Energy restriction

Intervention Type OTHER

Diet with LED and energy restricted diet with gradually inclusion of meals

Energy restriction delayed

delayed

Group Type OTHER

Energy restriction

Intervention Type OTHER

Diet with LED and energy restricted diet with gradually inclusion of meals

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Energy restriction

Diet with LED and energy restricted diet with gradually inclusion of meals

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Energy restriction delayed

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals with COPD, defined by the GOLD criteria, with a forced expiratory volume in one second (FEV1) \< 80% of predicted and a forced expiratory ratio of \<70, with a BMI ≥ 30 kg/m2

Exclusion Criteria

* patients with untreated cardiac disease, renal or hepatic failure, active cancer treatment, diabetes mellitus with prescribed insulin or patients with reported unintentional weight loss in the previous three months, or physical impairment that might affect the exercise capacity.
Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Göteborg University

OTHER

Sponsor Role collaborator

Sahlgrenska University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jenny van Odijk

Docent

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jenny van Odijk, Docent

Role: CONTACT

+46076-6183709

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SahlgrenskaUH03610

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.